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The pharmacological potential of rutin 31. Introduction
Medicinal plants are an integral part of traditional medicine
since ancient era. Drug discovery process has witnessed phyto-
chemicals for discovery of new leads (Grdina et al., 2002;
Weiss and Landauer, 2003; Arora et al., 2005). Flavonoids,
polyphenolic compounds, are one of the important classes of
plant derived chemicals that contain benzopyrone moiety.
About 4000 types of ﬂavonoids have been reported to be pre-
sent in plants (Guardia et al., 2001).
Rutin (3,30,40,5,7-pentahydroxyﬂavone-3-rhamnoglucoside,
Fig. 1) is a ﬂavonol, abundantly found in plants, such as pas-
sion ﬂower, buckwheat, tea, and apple. It is a vital nutritional
component of food stuff (Harborne, 1986). Rutin, also called
as rutoside, quercetin-3-rutinoside, and sophorin is a citrus ﬂa-
vonoid glycoside found in buckwheat (Kreft et al., 1997). The
name ‘rutin’ comes from the plant Ruta graveolens, which also
contains rutin. Chemically it is a glycoside comprising ofFigure 1 Chemical s
Please cite this article in press as: Ganeshpurkar, A., Saluja, A.K. The Pharmacolog
10.1016/j.jsps.2016.04.025ﬂavonolic aglycone quercetin along with disaccharide rutinose.
It has demonstrated a number of pharmacological activities,
including antioxidant, cytoprotective, vasoprotective, anticar-
cinogenic, neuroprotective and cardioprotective activities
(Javed et al., 2012; Richetti et al., 2011; Nassiri-Asl et al.,
2010; Mellou et al., 2006; Trumbeckaite et al., 2006;
Schwedhelm et al., 2003; Janbaz et al., 2002; La Casa et al.,
2000).
The present review focuses on the pharmacological poten-
tials as studied in various experimental models (see Table 1).
2. Pharmacological actions
2.1. Central nervous system
2.1.1. Prevention of neuroinflammation
Rutin has demonstrated the neuroprotective effect on brain
ischemia. Administration of rutin caused attenuation oftructure of rutin.
ical Potential of Rutin. Saudi Pharmaceutical Journal (2016), http://dx.doi.org/
4 A. Ganeshpurkar, A.K. Saluja‘ischemic neural apoptosis’ due to the embarrassment of p53
expression and lipid peroxidation along with increment in
‘endogenous antioxidant defense enzymes’ (Khan et al.,
2009). It has been found to be useful in hypoxic, glutamate
and oxidative stress (Pu et al., 2007). Reduction of ‘neuroin
ﬂammation’ in rat model of ‘sporadic dementia of Alzheimer
type’ (Javed et al., 2012) and neuroprotective effects in
‘dexamethasone-treated mice’ (Tongjaroenbuangam et al.,
2011) were observed on rutin administration.
2.1.2. Promotion of neural crest cell survival
The neural crest is progenitor comprising of neural and mes-
enchymal potentials. Treatment of rutin to trunk neural crest
cells increased their viability without altering cell differentia-
tion and proliferation which could be due to modulation of
ERK2 and PI3K pathways (Nones et al., 2012).
2.1.3. Sedative activity
CNS and behavioral activity of rutin were on hole board,
thiopental-induced sleeping time and locomotor activity tests
in mice. Rutin, given by intraperitoneal route caused a depres-
sant action on the CNS. Research conﬁrmed the CNS depres-
sant activity of rutin was unlikely due to the involvement of
GABAA receptor (Ferna´ndez et al., 2006).
2.1.4. Anticonvulsant activity
Rutin also possesses anticonvulsant activity and seems to be
safe for patients with epilepsy as it does not alter the activity
of any of the administered antiepileptic drugs nor demon-
strates any adverse effects (Nieoczym et al., 2014).
2.1.5. Anti-Alzheimer activity and treatment of hyperkinetic
movement disorder
Rutin suppressed activity of proinﬂammatory cytokines by
diminishing TNF-a and IL-1b production in microglia.
Such an effect seems to be useful in the treatment of Alz-
heimer’s disease as evident by prevention of b-amyloid oli-
gomeric cytotoxicity (Wang et al., 2012). Rutin caused
attenuation of streptozotocin-induced inﬂammation by
decreasing the activity of the glial ﬁbrillary acidic protein,
interleukin-8, cyclooxygenase-2, inducible nitric oxide syn-
thase and nuclear factor-kB and thereby prevented gross
anatomical changes in rat hippocampus. Such an effect
could be useful in averting cognitive deﬁcits and proves to
be beneﬁcial in the treatment of ‘sporadic dementia of Alz-
heimer type’ (Javed et al., 2012).
‘Tardive dyskinesia’ is a motor disorder of the orofacial
region raised due to chronic treatment with neuroleptic drugs,
and is considered as a chief clinical concern in the treatment of
schizophrenia. In a study, in haloperidol-induced orofacial
dyskinesia, rutin treatment reversed behavioral changes such
as orofacial dyskinetic movements, stereotypic rearing, loco-
motor activity, and percent retention along with restoration
of biochemical and neurochemical parameters. Thus, rutin
seems to be a lead molecule in the treatment of hyperkinetic
movement disorder (Bishnoi et al., 2007).
2.1.6. Antidepressant effects
Forced swimming test and tail suspension test in mice were uti-
lized to analyze ‘antidepressant-like effects’ of rutin isolatedPlease cite this article in press as: Ganeshpurkar, A., Saluja, A.K. The Pharmacolog
10.1016/j.jsps.2016.04.025from Schinus molle. There was a reduction in the immobility
time in the tail suspension test. There was no alteration in loco-
motor activity. Studies demonstrated the antidepressant-like
effect of rutin mediated due to increasing the availability of
serotonin and noradrenaline in the synaptic cleft (Machado
et al., 2008).
2.1.7. Stroke
Stroke could be regarded as a decisive public health issue that
seems to be an important cause of fatality and disability in
adults globally (Lloyd-Jones et al., 2009). Oxidative stress
and inﬂammation are two of the pathological events observed
after ‘ischemic injury’ in the brain (Deb et al., 2010). Protective
effect of rutin an animal model of focal cortical ischemia
induced by unilateral thermocoagulation of superﬁcial blood
vessels of the motor (M1) and somatosensory (S1) primary
cortices was studied. Rutin administration signiﬁcantly pro-
moted recovery of sensorimotor loss which was observed due
to the reduction of neurodegeneration in the periphery of cor-
tical injury (Ortolani et al., 1995).
2.2. Analgesic and antiarthritic activities
2.2.1. Analgesic and antinociceptive effects
Analgesic effect of rutin was studied by hot plate test on swiss
albino mice whereby the analgesic effect of rutin was estab-
lished (Rylski et al., 1979). Further, it was also conﬁrmed that
rutin exhibited peripheral and central antinociceptive activities
(Selvaraj et al., 2014).
2.2.2. Antiarthritic effects
Animals treated with rutin were observed with signiﬁcant
decrement in rheumatoid arthritis and Fanconi anemia by
inhibiting ‘oxygen radical overproduction’ (Ostrakhovitch
and Afanas’ev, 2001). In adjuvant arthritis rat model, rutin
inhibited acute and chronic phases of inﬂammation. Rutin
was the most active in the chronic stage of inﬂammation
(Guardia et al., 2001). Due to antifungal and anti-arthritic
effects, rutin has a therapeutic effect on septic arthritis caused
by Candida albicans (Han, 2009). Further in an independent
study, rutin slowed down inﬂammatory and catabolic cartilage
markers in osteoarthritic lesions in the Hartley guinea pig
(Horcajada et al., 2014).
2.3. Endocrine system
2.3.1. Antidiabetic effects
Streptozotocin is a toxic chemical known to deplete levels of
insulin by destroying pancreatic islets. Streptozotocin selec-
tively assaults pancreatic b-cells by generating free radicals
of oxygen and nitrogen monoxide along with reducing levels
of NAD and NADP. Excessive production of glucose and its
decreased utilization by tissues serve as the fundamental bases
of hyperglycemia (Chattopadhyay, 1993). In a study, chronic
administration of rutin in streptozotocin-induced diabetic rats
caused a decrement in plasma glucose, augmentation in insulin
levels, and restitution of glycogen content and glycolytic
enzymes. Signiﬁcant rejuvenation of pancreatic islets along
with diminished fatty inﬁltrate was observed in rutin-treated
diabetic rats (Stanley Mainzen Prince and Kamalakkannan,ical Potential of Rutin. Saudi Pharmaceutical Journal (2016), http://dx.doi.org/
The pharmacological potential of rutin 52006; Srinivasan et al., 2005). Diminution of fasting plasma
glucose, glycosylated hemoglobin, C-peptide, and malondi-
aldehyde levels was observed in rutin treated streptozotocin
diabetic rats (Kamalakkannan and Prince, 2006). Rutin
averted the levels of enzymes viz. ALT, AST, and LDH in
the serum, liver, and heart demonstrating a protective effect
on hepatic (Fernandes et al., 2010) and cardiac toxicity
(Krishna et al., 2005) associated due to streptozotocin. Alter-
ation in the activity of matrix metalloproteinase and protection
to kidney against streptozotocin-induced damage was
observed (Kamalakkannan and Stanely Mainzen Prince,
2006). Rutin stimulated glucose uptake in the soleus muscle,
and effect was thought to be mediated through extracellular
calcium and calcium-calmodulin-dependent protein kinase II
activation. Increase in intracellular calcium concentration is
involved in DNA activation which was mediated by rutin
(Kappel et al., 2013). Rutin added for glycemic control via
enhancement of insulin receptor kinase activity, thus aided in
promoting ‘insulin signaling pathway’ that caused increased
GLUT4 translocation and augmented glucose uptake (Hsu
et al., 2014).
2.3.2. Anti-hypercholesterolemic effects
Rutin is a ‘selective and non-toxic modulator’ of hypercholes-
terolemia. In a study conducted on diet-induced hypercholes-
terolemic Golden Syrian hamster model, rutin signiﬁcantly
reduced plasma triglyceride levels in experimental animals
(Kanashiro et al., 2009). Along with this, rutin also caused a
decrement in levels of total cholesterol and HDL cholesterol
(da Silva et al., 2001).
In a high-cholesterol diet fed male wistar rats, rutin admin-
istration demonstrated protective effect against the hepatotox-
icity as evident by decrement of the plasma level of alanine
transaminase (ALT), aspartate aminotransferase (AST),
triglyceride (TG), total cholesterol (TC), and low-density
lipoprotein (LDL) (Al-Rejaie et al., 2013). In another study,
it was established that chronic consumption of ﬂavonoids such
as rutin could be favorable to cardiovascular health
(Kalgaonkar et al., 2010).
2.3.3. Thyroid uptake promotion
‘Thyroid iodide uptake’ mediated via sodium-iodide sym-
porter plays a pivotal role in thyroid hormone biosynthesis
and also plays a key role in diagnosis and treatment of var-
ious thyroid diseases. However, some of the patients with
thyroid cancer are obstinate to radioiodine therapy, which
reduced iodine uptake ability, that remarkably reduces the
probability of endurance. Thus, it becomes necessary to
search for natural agents that aid in the uptake of thyroid
iodide.
In a study, rutin caused a minor reduction in levels of
serum T4 and T3 without changing serum thyrotropin. There
was a signiﬁcant increase in hypothalamic, pituitary and
brown adipose tissue type 2 deiodinase along with the diminu-
tion of liver type 1 deiodinase activities. Administration of
rutin was observed with increment in thyroid iodide uptake
that could be due to an elevation in the activity of sodium-
iodide symporter. The study demonstrates the effectiveness
of rutin as an adjuvant in radioiodine therapy (Gonc¸alves
et al., 2013).Please cite this article in press as: Ganeshpurkar, A., Saluja, A.K. The Pharmacolog
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2.4.1. Hypertension
Buckwheat, a rich source of rutin is found to prevent oxidative
damage in ‘aortic endothelial cells’ by lowering nitrotyrosine
immunoreactivity. Germinated extract of buckwheat demon-
strated antihypertensive effect and possibly shelter ‘arterial
endothelial cells’ by detrimental effects of oxidative stress
(Kim et al., 2009). Reduction in oxidative stress due to rutin,
when administered by oral route, is the key reason for the
restoration of ‘impaired baroreﬂex sensitivity’ and ‘vascular
reactivity’ in hypertensive rats (Mendes-Junior et al., 2013).
By augmenting NO production in human endothelial cells,
rutin improved endothelial functions (Ugusman et al., 2014).
2.4.2. Blood coagulation
Chan et al. (2009) attempted to study effects of the rutin on the
anticoagulant activity of oral warfarin and the protein binding
along with pharmacokinetics of its enantiomers in rats. Rutin
enhanced the in vitro serum protein binding of S- and R-
warfarin. Rutin treatment signiﬁcantly decreased the elimina-
tion half-life of S-warfarin by 37% as a result of the 69%
increase in unbound clearance of the S-enantiomer. In a nut-
shell, concomitant administration of rutin possibly reduces
the anticoagulant effect of racemic warfarin (Chan et al.,
2009).
2.4.3. Antiplatelet aggregatory effect
Rutin in vitro caused concentration-dependent inhibition of
platelet activating factor induced washed rabbit platelet aggre-
gation, and intra-platelet free calcium concentration elevation
was induced by platelet activating factor which was inhibited
by rutin in a dose-dependent manner (Chen et al., 2002).
2.5. Gastrointestinal system
2.5.1. Antiulcer effects
A peptic ulcer is inﬁrmity that inﬂuences the substantial pop-
ulation in the world. Ulcers are observed when disparity occurs
among ‘aggressive’ and ‘protective’ factors at the luminal sur-
face of the gastric epithelium. HCl, pepsins, nonsteroidal anti-
inﬂammatory drugs, Helicobacter pylori, bile acids, ischemia,
hypoxia, smoking, alcohol, etc. include dynamic features
whereas defensive factors comprise of bicarbonate, a mucus
layer, mucosal blood ﬂow, PGs and growth factors (Kalant
et al., 2007).
Ethanol is ill-reputed agent known to produce damage to
gastric mucosa in animal and clinical studies. Ethanol in a con-
centration higher than 400 ml/l causes signiﬁcance in gross
morphology of stomach which is observed by mucosal hyper-
emia, necrosis, edema and mucosal or submucosal hemorrhage
(Oates and Hakkinen, 1988; Szabo and Goldberg, 1990).
Oxygen-derived free radicals could be regarded as a key reason
for the formation of lesions (Pihan et al., 1987; Szelenyi and
Brune, 1988). Rutin pretreatment before administration of
ethanol afforded signiﬁcant protection against necrosis.
Restoration in the levels of glutathione peroxidase along with
‘anti-lipoperoxidant effect’ was observed (La Casa et al.,
2000). Similarly in an indomethacin-induced model of ulcers,
rats pretreated with rutin caused reestablishment of alteredical Potential of Rutin. Saudi Pharmaceutical Journal (2016), http://dx.doi.org/
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neutrophil inﬁltration, suppression of oxidative stress genera-
tion and replenishing nitrite/nitrate levels. Protective effects
are also evident by histopathological investigations (Abdel-
Raheem, 2010).
Another investigation provides insight into the molecular
mechanism of action of rutin over gastric proton pumps. Rutin
demonstrated concentration-dependent inhibition of goat gas-
tric ATPase, with IC50 = 36 lg/ml, making it that rutin exerts
an antiulcer effect by inhibiting the gastric proton pump
(Dubey et al., 2013a,b).
2.6. Respiratory system
2.6.1. Antiasthmatic activity and other associated effects
The antiasthmatic activity of rutin was studied in ovalbumin-
sensitized conscious guinea pigs challenged with aerosolized
ovalbumin where airway resistance during the immediate
phase response and late-phase response was determined. Rutin
signiﬁcantly inhibited speciﬁc airway resistance and
immediate-phase response along with reticence of histamine,
phospholipase A2, and eosinophil peroxidase. There was
reduced conscription of neutrophils and eosinophils into the
lung (Jung et al., 2007). Use of rutin was also suggested in
whooping cough along with vitamins C and K (De Sarmento
and Kimura, 1957). In cats and whippets, rutin has been effec-
tively used in the management of idiopathic chylothorax
(Kopko, 2005; Gould, 2004; Schuller et al., 2011).
2.7. Bones
2.7.1. Antiosteoporotic and antiosteopenic effect
Osteoporosis is a skeletal disorder observed by a decrement in
bone strength, that is associated with augmented risk of fracture
(Bhutani and Gupta, 2013). This condition is affecting elderly
citizens globally and seems to be budding health predicament.
Osteoporosis is observed in the case when bone resorption by
osteoclasts surpasses bone formation by osteoblasts (Lau and
Guo, 2011; Roux, 2010). All therapeutic strategies for treatment
of osteoporosis emphasize inhibition of ‘osteoclast-mediated
bone resorption’. Parathyroid hormones are only classes of
agents that ‘stimulate bone formation’ (Hodsman et al., 2005).
In osteogenic-related assays, rutin caused proliferation and dif-
ferentiation of human osteoblast-like MG-63 cells. There was
also increase in the activity of alkaline phosphatase, expression
of collagen type I and degree of mineralization (Hyun et al.,
2014). Similar effects have been observed with rat calvarial
osteoblast cells (Yang et al., 2006). Rutin inhibits osteoclast for-
mation by decreasing oxygen reactive species and TNF-alpha
by inhibiting activation of NF-kappaB (Kyung et al., 2008).
Rutin inhibits ovariectomy-induced osteopenia in rats by slow-
ing down resorption and increasing osteoblastic activity
(Horcajada-Molteni et al., 2000). Thus, rutin can also be
regarded as ‘osteoblast stimulant’.
2.8. Eye
2.8.1. Anticataract and ophthalmic effect
Formation of advanced glycation end products (AGE) is asso-
ciated with cataract, a diabetic complication. Thus, inhibitionPlease cite this article in press as: Ganeshpurkar, A., Saluja, A.K. The Pharmacolog
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complication. In this study, rutin caused embarrassment of
glycation of proteins, chelation of metal complexes and partly
inhibiting post-Amadori formation (Muthenna et al., 2010). In
another study in wistar rat pups, selenium was used to induce
cataract and protective effect of rutin in retarding cataractoge-
nesis was investigated. Eye lens of rats treated with rutin were
observed with restoration of lenticular antioxidant enzymes
along with decrement in malondialdehyde formation. Experi-
mental outcomes suggest that rutin prevented cataractogenesis
possibly due to antioxidant mechanism (Isai et al., 2009).
Oral administration of rutin has been observed with an
improved reduction in intraocular pressure (Vetrugno et al.,
2012). Involvement of vitamins B1, B2, forskolin, and rutin
demonstrates ‘defending effect’ on the ocular surface which
aids to re-establish a ‘normal equilibrium’ of the tear ﬁlm
altered due to toxins (Nebbioso et al., 2013).
2.9. Excretory system
2.9.1. Diuretic effect
Quercetin, a metabolite of rutin, which is abundantly found in
Hibiscus sabdariffa Linn acted on vascular endothelium caus-
ing nitric oxide release, leading to increasing renal vasorelax-
ation by increasing kidney ﬁltration (Alarco´n-Alonso et al.,
2012).
2.10. Reproductive system
2.10.1. Effect on sperm quality and male reproductive organs
Rutin, in a study, afforded protective effect on damage to
human sperm induced by lipid peroxidation (Moretti et al.,
2012). Rutin also demonstrated possible protection to testicu-
lar tissue and reproduction from oxidative stress observed in
type 1 diabetes mellitus (Butchi Akondi et al., 2011) along with
amelioration of cyclophosphamide-induced reproductive toxi-
city (Abarikwu et al., 2012) and testicular ischemia–reperfu
sion-induced oxidative stress in rats (Akondi et al., 2011).
2.11. Anticancer effects
Cancer includes a group of diseases that are characterized by
the abnormal growth of cells that latently assault or spread
to other parts of the body (Markert and Markert, 1968). Fla-
vonoids are known to demonstrate an extensive assortment of
biological effects, comprising of ‘antioxidant and radical-
scavenging activities’. Reactive oxygen species have been asso-
ciated with the pathogenesis of several diseases such as
atherosclerosis and certain cancers.
Rutin has been extensively studied for anticancer/antineo-
plastic effects. In a study, human leukemia HL-60 cells were
implanted in a murine model, and rutin (dose 120 mg/kg)
caused a signiﬁcant reduction in tumor size justifying antileuke-
mic potential (Lin et al., 2012). In an independent study, rutin
when administered to SW480 tumor cell lines (human colon
cancer cell lines), was observed with less detrimental effects
on the body and relative organ weight in mice along with an
increment of mean survival time of 50 days (Alonso-Castro
et al., 2013). Chem et al., demonstrated anti-
neuroblastoma effect of rutin, where, rutin signiﬁcantly inhib-
ited the growth of LAN-5 cells and chemotactic ability. Theical Potential of Rutin. Saudi Pharmaceutical Journal (2016), http://dx.doi.org/
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and BCL2/BAX ratio along with a reduction in levels of
MYCN mRNA level and the secretion of TNF-a (C.Y. Chen
et al., 2013). Rutin is also known to inhibit cancer cell growth
by cell cycle arrest and/or apoptosis, along with inhibition of
proliferation, angiogenesis, and/or metastasis in colorectal cell
lines (Arau´jo et al., 2011). Rutin analog, quercetin, is studied
against the proliferation of the ovarian cancer cell line OVCA
433, where dose-related inhibition was observed (Scambia
et al., 1990). In another study, quercetin augmented apoptosis
and barred metastasis in a model of pancreatic cancer
(Mouria et al., 2002). Rutin also seems to be useful as an adju-
vant in radioiodine therapy (Gonc¸alves et al., 2013).
2.12. Chemotherapeutic activity
2.12.1. Antibacterial activity
Rutin is extensively studied for antimicrobial activity against
various strains of bacteria. It has demonstrated a profound
degree of inhibition on growth of bacteria Escherichia coli
(Araruna et al., 2012). Rutin, quantiﬁed in honey has shown
inhibitory effects overProteus vulgaris,Shigella sonnei andKleb-
siella sp. (Pimentel et al., 2013). Antimicrobial activity against
Pseudomonas auruginosssa and Bacillus subtilis has also been
documented (Dubey et al., 2013a,b). In situ antimicrobial activ-
ity of rutin and other polyphenols in the food system has been
studied, and the results demonstrate a promising involvement
of ﬂavonoids in the preservation of food (Stojkovic´ et al., 2013).
Bernard et al., demonstrated that rutin by inhibiting DNA
isomerase IV demonstrated antibacterial activity against E.
coli (Bernard et al., 1997). In a study, rutin synergistically
enhanced antibacterial activity of other ﬂavonoids against
Bacillus cereus and Salmonella enteritidis. Minimum inhibitory
concentration value for kaempferol was remarkably decreased
by the addition of rutin (Arima et al., 2002).
2.12.2. Antifungal activities
Rutin demonstrated antifungal activity against the strain of
Candida gattii with a minimum inhibitory concentration of
60 lg/ml (Johann et al., 2011). It was suggested that chemical
modiﬁcation in rutin by the introduction of substitute group
may alter physicochemical properties such as electron density,
hydrophobicity and steric strain that may prove to be fruitful
regarding increment of antifungal activity. Use of rutin in
treatment of septic arthritis caused by C. albicans has also been
suggested (Han, 2009).
2.12.3. Antimycobacterial activity
In a study, ﬂavonoids rich extract containing rutin demon-
strated antimycobacterial activity against Mycobacterium
smegmatis (da Cruz et al., 2012).
2.12.4. Larvicidal activity
In a study, rutin signiﬁcantly inhibited growth and propaga-
tion of larvae of S. aegypti where maximum mortality of larvae
was observed at 72 h (Dubey et al., 2013a,b).
2.12.5. Antimalarial activity
Antimalarial effect of rutin in association with chloroquine
was observed on white leghorn chickens infected withPlease cite this article in press as: Ganeshpurkar, A., Saluja, A.K. The Pharmacolog
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In another study, biochemical mechanism of the antimalarial
activity of Azadirachta indica leaf extract revealed the presence
of an abundant amount of quercetin, an active metabolite of
rutin (Iwu et al., 1986). Recently, the antiplasmodial activity
of quercetin is documented against Plasmodium falciparum
(Ganesh et al., 2012).
2.12.6. Antiretroviral activity
In a study, sodium rutin sulfate, a sulfated rutin analog, was
investigated for anti-HIV activity against HIV-1 X 4 viruses
IIIB, HIV-1 R5 isolates Ada-M and Ba-L strains. The mecha-
nism by which sodium rutin sulfate demonstrated antiretrovi-
ral effect was a blockade of viral entry and virus-cell fusion
which was mediated via interaction with HIV-1 envelope gly-
coprotein (Tao et al., 2007).
2.12.7. Antiviral activity
Antiviral agents for the treatment of infections caused by
retroviruses, orthomyxoviruses, herpes viruses, hepatitis B
virus and hepatitis C virus are widely available (De Clercq
and Field, 2006). Owing to the high incidence of viral infec-
tions along with no precise treatment for ‘appearance of new
resistant viral strains’, its seems to be necessary to develop
novel antiviral drugs.
Rutin has been tested against vesicular stomatitis virus on
mouse ﬁbroblasts and protected cells for about 24 h (Wacker
and Eilmes, 1978). In the case of canine distemper virus infec-
tion, rutin affords immense viral embarrassment when added
at the times of adsorption and penetration in the viral replica-
tive cycle (Carvalho et al., 2013). Rutin a chief constituent of
Capparis sinaica Veill demonstrated profound antiviral effect
against avian inﬂuenza strain H5N1 using plaque inhibition
assay in the Madin-Darby canine kidney (Ibrahim et al., 2013).
2.13. Hair
Apoptosis of hair follicular cells is a leading cause of hair fol-
licle degeneration. In a study, apoptosis of human follicular
dermal papilla cells was observed after treatment with stau-
rosporine; this event was completely introverted by exposure
to rutin, spermidine, and zeaxanthin. There was the preserva-
tion of expression of anti-apoptotic molecules such as Bcl-2,
MAP-kinases and their phosphorylated forms, which con-
cludes the use of rutin in the prevention of apoptosis of hair
follicular cells, one of the leading causes of baldness (Carelli
et al., 2012).
2.14. Skin
2.14.1. Sunscreen effects
The desire for having healthy, beautiful and disease free skin is
being observed from the eternal era. History of cosmetics and
skin care product dates back in ancient Greek, Roman and
Egyptian civilization. Advances in sciences and technology
along with the development of modern chemistry have made
this dream easy (Draelos, 2000). Exposure to ultraviolet B
radiations produces ‘oxidative and inﬂammatory skin damage’
and augments jeopardy of skin ‘carcinogenesis. Rutin has been
studied to explore the effects of rutin on UVB-inducedical Potential of Rutin. Saudi Pharmaceutical Journal (2016), http://dx.doi.org/
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rutin on mice skin 30 min before UVB irradiation reduced epi-
dermal hyperplasia and the levels of proteins. There was also
signiﬁcant inhibition of UVB-induced expression of
cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase
(iNOS) which could be due to inhibition of p38 MAP kinase
and JNK that caused diminution UVB-induced expression of
COX-2 in mouse skin (Choi et al., 2014). In a study conducted
by Choquenet et al. (2008), rutin when incorporated in oil-in-
water emulsions (concentration 10% w/w), sun protection fac-
tor (SPF) values comparable to ‘homosalate’ were observed.
Along with TiO2, SPF values approached to 30.
2.14.2. In atopic dermatitis
In an atopic dermatitis model in BALB/c mice by repeated
local exposure of house dust mite (Dermatophagoides farinae)
extract (DFE) and 2,4-dinitrochlorobenzene (DNCB) to the
ears, rutin treatment caused suppression of interleukin (IL)-
4, IL-5, IL-13, IL-31, IL-32 and interferon (INF)-c in the tis-
sue. In 2,4-dinitroﬂourobenzene-sensitized a local lymph node
assay for allergic contact dermatitis, rutin caused suppression
of allergic contact dermatitis based on ear thickness and lym-
phocyte proliferation, serum IgG2a levels, and expression of
INF-c, IL-4, IL-5, IL-10, IL-17 and tumor necrosis factor-a
in allergic contact dermatitis ears. This study signiﬁes anti-
atopic dermatitis and allergic contact dermatitis activity of
rutin (Choi and Kim, 2013). Rutin has also demonstrated anti
aging effects on the skin (Odetti et al., 1990). Thus, rutin could
be regarded as most effective topically applied compound
given its antioxidant activity and skin penetration proﬁle
(Alonso et al., 2014).
2.15. Immune effects
Vibrio alginolyticus challenge was studied based on immune
and physiological response to rutin in white shrimp. In this
study, physiological, innate non-speciﬁc immune responses,
respiratory bursts and superoxide dismutase activity against
the pathogen were analyzed. Rutin from Toona sinensis was
administered to shrimp. In brief, shrimps treated with rutin
maintained lower glucose, lactate, and lipid levels in response
against the pathogen. Survival rates of shrimps treated with
rutin were more (Hsieh et al., 2008). Another study demon-
strates promotion of the activity of macrophage phagocytosis
in cells (Lin et al., 2009).
2.16. Body strength
2.16.1. Anti fatigue activity
Fatigue is an indication which is associated with person’s
health. Fatigue is related to deterioration in ‘physical perfor-
mance’. Extreme exercise is associated with accretion of sur-
plus reactive free radicals that leads to an oxidative stress
injury to the body. Depletion of energy along with the accumu-
lation of excess metabolite is the key reasons for fatigue (Yu
et al., 2010; Fitts, 1994; Coombes et al., 2002; You et al.,
2011). Rutin administration in mice prevented depletion of
superoxide dismutase and reduced glutathione. After seven
days of treatment with rutin, mice were sacriﬁced and analyzed
for soleus muscle and brain for peroxisome proliferator-
activated receptor-a coactivator and sirtuin one mRNAPlease cite this article in press as: Ganeshpurkar, A., Saluja, A.K. The Pharmacolog
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interacting protein 1, myelin basic protein, Rho GDP dissoci-
ation inhibitor (GDI) alpha, and TPI indicated
that rutin treatment inhibited condition anxiety via up-
regulation of the expression of anxiety-associated proteins
(Su et al., 2014) and hence in nutshell it can be regarded as
treatment with rutin improves the various mutilations allied
with physical fatigue.
2.17. Organ protective effects
2.17.1. Neuroprotective activity
In mice model, rutin inhibited oxaliplatin-induced chronic
painful peripheral neuropathy. Oxaliplatin is one of the most
important platinum compounds used in colorectal cancer
chemotherapy. However, it suffers from a drawback of periph-
eral which seems to be difﬁcult to treat. Rutin signiﬁcantly
decreased oxaliplatin-induced peroxidative changes in the
spinal cord and lipid peroxidation along with inducible nitric
oxide (Azevedo et al., 2013).
2.17.2. Retinoprotective activity
Effect of rutin on ocular blood ﬂow by ‘colored microsphere
technique’ was determined. Electroretinography was used to
determine the b-wave recovery which is a tool for estimation
of retinal function recovery. Rutin increased ocular blood ﬂow
and demonstrated a remarkable effect on retinal function
recovery (Chiou and Xu, 2004).
2.17.3. Protective effect on lung tissue
Acute lung injury is severe disease observed with ‘high mortal-
ity and morbidity.’ Till date, there is no therapeutic stratagem
established. Rutin demonstrated protective effects on
histopathological changes in lung tissue along with prevention
of ‘inﬁltration of polymorphonuclear granulocytes in bron-
choalveolar lavage ﬂuid’. There was also a reduction in secre-
tion of lipid peroxidation and proinﬂammatory cytokines. The
activity of antioxidant enzymes such as catalase, glutathione
peroxidase, superoxide dismutase, and heme oxygenase-1
caused by lipopolysaccharide was reversed by rutin (Yeh
et al., 2014). Pretreatment of rutin caused inhibition of
lipopolysaccharide-induced arterial blood gas exchange and
neutrophils inﬁltration in the lungs. There was suppression
of macrophage inﬂammatory protein-2 and matrix
metalloproteinase-9 (Chen et al., 2014). Another study demon-
strated that rutin effectively inhibited vascular cell adhesion
molecule-1 and inducible nitric oxide synthase (Huang et al.,
2014). There is also evidence that rutin prevented early adult
respiratory distress syndrome possibly due to inhibition of
lipid peroxidation (Ortolani et al., 2000).
2.17.4. Cardioprotective effects
Ischemic heart disease is one of the primary reasons for ‘mor-
bidity and mortality’ all along the globe. The pathophysiology
underlying damage at a cellular level raised due to ischemia is
multifaceted. ‘Reactive oxygen species’ are identiﬁed to partic-
ipate and play a key task in the pathogenesis of several diseases
(Li and Jackson, 2002). It is well known that ischemic tissues
produce ‘oxygen-derived free radicals’ that are known to cause
oxidative damage to membrane lipids, proteins, andical Potential of Rutin. Saudi Pharmaceutical Journal (2016), http://dx.doi.org/
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alterations’ of the myocardium (Burton et al., 1984). Rutin was
studied for cardioprotective effect by ischemia–reperfusion-in
duced myocardial infarction in normal and streptozotocin dia-
betic rats. Rutin administration signiﬁcantly offered cardio-
protection and restricted infracts size in normal and diabetic
rats (Annapurna et al., 2009; Krishna et al., 2005). The mech-
anism lying behind this protection could be attenuation of lipid
peroxidation in myocardial tissues (Ali et al., 2009).
Isoproterenol is b-adrenergic agonist used to treat brady-
cardia and heart block (Shen, 2008). However, frequent
administration of it may lead to cardiac toxicity observed by
an increase in the activity of serum cardiac marker enzymes
viz lactate dehydrogenase, aspartate transaminase, creatine
kinase, and alanine transaminase along with signiﬁcant
decrease in the activity of these enzymes in the heart. Rutin
restored the levels of cardiac marker enzymes along with a
reduction in lipid peroxidation. The study suggests the cardio-
protective effect is due to the virtue of the antioxidant effect of
rutin (Chan et al., 2009).
Repression of isoproterenol-induced increase in
angiotensin II and aldosterone in plasma was observed after
administered by rutin. Along with this, overexpression of
transforming growth factor b1, connective tissue growth fac-
tor, and excessive deposition of extracellular matrix in
isoproterenol-treated myocardial tissues was observed in the
group of animals treated with rutin (Li et al., 2013).
2.17.5. Prevention of splenocyte apoptosis
Rutin is known to alter the viability and function of mitogen-
stimulated splenocytes and thymocytes compared with non-
stimulated cells. In a study, when splenocytes were cultured
with mitogens, it was observed that there was a decrease in
interferon-gamma production along with decrement in spleno-
cyte apoptosis (Roseghini et al., 2007).
2.17.6. Hepatoprotective activity
Cirrhosis is the destruction of hepatocytes and following sub-
stitution with ‘scar tissue’ which alter the ﬂow of blood
through liver leading to the death of hepatocytes and n func-
tion of the liver (Wang and Nagrath, 2010). The event of liver
damage is followed by ‘hepatic ﬁbrosis’ whereby regeneration
of apoptotic cells is observed after ‘repeated injury’ (Friedman
et al., 2002). In the event, when the death of regenerating cells
occurs, deposition of extracellular matrix is observed, which
leads to deposition of ‘ﬁbrillar collagen’ (O’Connell and
Rushworth, 2008). Such pathology is difﬁcult to treat. The
effectiveness of treatment with colchicines, interferons, penicil-
lamine and corticosteroids are contradictory and seem to be
questionable. As oxidative stress is one of the causes beneath
cirrhosis, use of antioxidants could be a unique strategy for
treatment. Rutin is extensively studied for hepatoprotective
activity in experimental animals. Khan et al. (2012a,b) evalu-
ated the protective effect of rutin in carbon tetrachloride
(CCl₄)-induced liver injuries in rats. Administration of rutin
caused a decrement in levels of alanine aminotransferase,
aspartate aminotransferase, alkaline phosphatase and
gamma-glutamyl transpeptidase in serum raised due to
carbon tetrachloride. The level of cholesterol in blood was
regulated whereas the level of endogenous liver antioxidant
enzymes such as catalase, superoxide dismutase, glutathionePlease cite this article in press as: Ganeshpurkar, A., Saluja, A.K. The Pharmacolog
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and glutathione was increased, whereas lipid peroxidation
was decreased in a dose-dependent manner. Along with this,
the activity of p53 and CYP2E1 was restored by treatment
with rutin. In an independent study in BALB/c mice, rutin
treatment allayed oxaliplatin-induced hepatotoxicity and
neurotoxicity. Prevention of mechanical allodynia along with
histopathological observations suggested the protective role
of rutin in the prevention of hepatotoxicity (Schwingel et al.,
2014).
2.17.7. Nephroprotective activity
Nephropathy is one of the most encountered pathogenesis
observed in the populace all over the world regardless of
age, caste, creed, race and environment. The reasons behind
this condition result from anomalies rose due to different
metabolic and physiological disturbances. Nephropathy is
among the ten primary causes of death all along the globe
(Zhang and Lindup, 1993). Gentamicin (Sonkar et al., 2014),
ecstasy (Karami et al., 2014), cisplatin (Corcostegui et al.,
1998), and carbon tetrachloride (Ogeturk et al., 2005) are some
of the compounds known to demonstrate nephrotoxicity.
In a study, rutin demonstrated protective activity against
oxonate-induced hyperuricemia and renal dysfunction in mice.
Administration of rutin resulted in a the decrement in levels of
serum urate, creatinine and blood urea nitrogen, serum and
kidney uromodulin levels, and increased urine uromodulin,
urate and creatinine excretion in hyperuricemic mice. There
was a signiﬁcant downregulation of mRNA and protein levels
of mouse glucose transporter 9 and urate transporter 1, along
with upregulation of mRNA and protein levels of organic
anion transporter 1 and organic cation/carnitine transporters
in the kidney of hyperuricemic mice. In a fructose-fed rat
model for hyperuricemia, rutin blocked the NOD-like receptor
three inﬂammasome activation and aided in the improvement
in the signaling and reduced lipid accumulation in the kidney
of rats (Hu et al., 2012) along with reversal of dysregulation
of renal transporters (Hu et al., 2009). Inhibition of inducible
nitric oxide synthase activity and reduction in 3-nitrotyrosine
formation (Korkmaz and Kolankaya, 2013) along with inhibi-
tion of reactive oxygen species (Korkmaz and Kolankaya,
2010) in the kidneys seem to be an important approach to pre-
vent renal ischemia/reperfusion injury.
In cisplatin-treated wistar rats, rutin pretreatment caused
restoration of kidney function and oxidative stress biomarkers
(Kamel et al., 2014). It partially inhibited effect on NFjB and
TNF-a pathway mediated inﬂammation, caspase-3 mediated-
tubular cell apoptosis, along with re-establishment of
histopathological changes due to cisplatin administration
(Arjumand et al., 2011). Rutin also demonstrated protective
effects against potassium bromate-induced nephrotoxicity in
rats. The decrement in DNA fragmentation, upregulation in
the activity of antioxidant enzymes viz. catalase, superoxide
dismutase, glutathione peroxidase, glutathione-S-transferase,
glutathione reductase, and reduced glutathione along with a
reduction in lipid peroxidation were observed (Khan et al.,
2012a,b).
2.17.8. Protective effect on blood vasculature
Rutin was found to resist damages in vascular beds due to a
disturbance in myocardium supply leading to initial damage,ical Potential of Rutin. Saudi Pharmaceutical Journal (2016), http://dx.doi.org/
Table 1 Anticancer effects of rutin on different cell lines.
Cell line Type Signiﬁcant beneﬁt
achieved
Reference
HL-60 Leukemia Signiﬁcant reduction
in tumor size
Lin et al.
(2012)
SW480 Colon cancer Less harmful eﬀects on
body weight and
relative organ weight
in mice, increased
mean survival time
Alonso-
Castro
et al.
(2013)
LAN-5 Neuroblastoma Decreased BCL2
expression and BCL2/
BAX ratio along with
reduction in levels of
Y.S. Chen
et al.
(2013)
10 A. Ganeshpurkar, A.K. Salujahowever in a chronic model of ‘stenocardia in dogs,’ therapeu-
tic effect of rutin is up to a limited extent (Pozin et al., 1996).
2.18. Protective effects on wounds
2.18.1. Wound healing activity
Rutin, formulated as hydrogel, when applied to skin lesions of
rats, caused a decrease in wound area as compared to control
hydrogels. There was a reduction in oxidative stress in wound
area as signiﬁed by a reduction in lipid peroxidation and pro-
tein carbonyl content along with increased catalase activity
(Almeida et al., 2012). Rutin-releasing chitosan hydrogels as
injectable dressings for dermal wound healing have been for-
mulated. These hydrogels promoted deﬁned formation of
neo-epithelium and thicker granulation, which is closer to
the original epithelial tissue (Tran et al., 2011).
2.19. Radio modulatory effects
Radiation therapy is one of the principal strategies in anti-
cancer therapy for treatment of various cancers; however,
due to ill effects on normal tissues, its use is restricted. Ionizing
radiations predispose to the generation of free radicals that
damages DNA; cell death follows this event. Thus along with
cancerous cells, the damage is observed with normal cells also.
Some ‘radioprotectors’ have been screened; still, their clinical
effectiveness is restricted due to toxicity with the frequent
administration. In a study, rutin has been investigated for
potential radioprotective effects. Rutin was administered to
Swiss albino mice to assess its impact on ‘radiation-induced
sickness along with the survival analyses’. Rutin at the dose
of 10 mg/kg optimally demonstrated radioprotective effects.
There was an increment in radiation tolerance and levels of
antioxidant enzymes were restored along with a decrease in
lipid peroxidation in liver (Patil et al., 2012). Similar protection
by rutin against gamma radiations was also observed (Patil
et al., 2013).
2.20. PharmacokineticsMYCN mRNA level
P
1Absorptionlease cite this ar
0.1016/j.jsps.201Intestine
and the secretion of
TNF-a
ticle in press as: Ganeshpurkar, A.
6.04.025Andlauer et al.
(2001), Carbonaro
and Grant (2005)
CRC Colorectal Cell cycle arrest and/ Arau´joDistributionor apoptosis et al.
35 ± 2 lmol/1(as quercetin)
1.35 ± 0.37 microg/mLChen et al. (2010)(2011)Metabolism
B16F10 Pulmonary
metastasis
Reduction in the
number of metastatic
nodules
Martı´nez
Conesa
et al.
(2005)
B16
melanoma
Melanotic
melanoma
Augmentation of
tumor mass, inhibition
of melanin formation
Drewa
et al.
(1998)
HTC Hepatic Cytotoxic eﬀect CristinaMetabolites are 3,4-
dihydroxyphenylacetic acid,
3,4-dihydroxytoluene, m-
hydroxyphenylacetic acid,
3-methoxy-4-
hydroxyphenylacetic acid/
homovanillic acid, and 3,5,
7,30,50-pentahydroxyﬂavo
nol/quercetinPashikanti et al.
(2010)hepatic carcinoma MarcariniExcretion
cells et al.About 10% in urine, rest
unchanged in foeces
(2011)Choudhury et al.
(1999), Griﬃths and
Barrow (1972), Saluja, A.K. The Pharmacolog2.21. Drug interaction
Absorption of paclitaxel is increased when concurrently
administered with rutin (Kumar et al., 2015). Rutin treatment
cause increased the body’s resistance to drugs due to induction
of the drug metabolizing enzymes in the liver; such an action
has about the same magnitude with that of phenobarbital
and pregnenolone-16 alpha-carbonitrile (Kourounakis and
Rekka, 1986).
2.22. Safety pharmacology
Rutin has been studied for carcinogenicity and results have
demonstrated practically and signiﬁcantly no carcinogenic
potential in non-inbred golden hamsters (Morino et al., 1982).
2.23. Structure–activity relationship
 4-Oxo group and the 2,3 double bond in the C ring in rutin
may be related by its neuroprotective action (Khan et al.,
2009).
 The presence of sugar moiety (O-rha-glu) has no signiﬁ-
cant effect on the ileum, which indicates that presence of
sugar substitution diminishes the biological activity of the
ﬂavonoids (Hammad and Abdalla, 1997).ical Potential of Rutin. Saudi Pharmaceutical Journal (2016), http://dx.doi.org/
The pharmacological potential of rutin 11 Hydroxyl group in 5-position as well as the double bond
and the double-bonded oxygen in the oxane ring is all
necessary for the overall ability of ﬂavonoids to inhibit
phospholipase A2 activity, and that the hydroxyl groups
in 3’- and 4’-position are required for selective inhibition
of phospholipase A2-II (Lindahl and Tagesson, 1997).
 Polyhydroxylated substitutions on rings A and B, a 2,3-
double bond, a free 3-hydroxyl substitution and a 4-keto
moiety, confer antiperoxidative properties to rutin (Ratty
and Das, 1988).
 Catechol group in the B-ring, a double bond between C2
and C3 at the C-ring, and ketone group in C4 at the C-
ring are necessary for inhibitory effect on angiotensin-
converting enzyme activity (Guerrero et al., 2012).
 Rutin, whose C-3 position is glycosylated has a less free
radical neutralizing activity that is aglycone quercetin (H.
C. Chen et al., 2013).
 The glycosylation decreases the AChE inhibitory activities
of ﬂavonoids and lowers the afﬁnities for AChE by 1–5
times depending on the conjunction site and the type of
sugar moiety (Xie et al., 2014).
 The presence of a phenolic group in rutin is known to add
hydrogen donation for scavenging the radiation-induced
radicals, and to inhibit radiation-induced oxidative stress
(Patil et al., 2013).
 The presence of a glycosylation group in rutin greatly
reduces vascular relaxation effect in porcine coronary artery
(Xu et al., 2007).3. Conclusion
As evident from aforesaid facts, rutin is phytochemical with
multiple pharmacological activities. An ancient saying ‘an
apple a day, keeps doctor away’ seems to be true as rutin,
one of the important constituents of apples, has a wide array
of biological activities. Hence, rutin can be regarded as a ‘vital
phytochemical’ which is needed to be studied extensively to
establish effective safety proﬁle in human to get therapeutic
beneﬁts.
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